Biotech CEO Who Built a Cancer Company Got Cancer Himself
Dyve Biosciences CEO Dr. Ryan Beal was diagnosed with rare thymoma mid-ultramarathon after losing his mother to cancer. Two years of treatment rebuilt his company's mission.
By Amara Osei
4 min read

What's News
- Dr. Ryan Beal co-founded Dyve Biosciences in 2014; the company delivers therapeutics through the skin to target tumor acidity.
- Beal was diagnosed with thymoma, a rare thymus cancer, at age 49 during a 120-mile race in Colorado.
- His mother survived breast cancer but died of pancreatic cancer within weeks of diagnosis, eight years later.
- Beal took a two-year sabbatical from Dyve during cancer treatment.
- Beal holds an MD from the University of Pennsylvania and worked at McKinsey before founding startups.
Dr. Ryan Beal, CEO of the cancer-focused biotech Dyve Biosciences, was 60 miles into a 120-mile race in Colorado when chest pain forced him to stop. Doctors in Vail diagnosed him with thymoma — a rare cancer of the thymus gland, which sits in the middle of the chest. He was 49 and, weeks earlier, had been fit enough to train for a six-day run through the Rockies.
The diagnosis landed with brutal timing. His mother had just died of cancer; her celebration of life was held days before the race. Beal and his brother had considered canceling the event but decided to run it together to reflect on her life.
"To say it was a shock is an understatement," Beal said. "But I had something few cancer patients do: I'm the CEO of a cancer-focused biotech company. I immediately sent my results to three doctor friends, and they got to work."
From medical school to McKinsey to a startup
Beal describes himself as a lifelong science nerd who grew up wanting to be a physician. At medical school at the University of Pennsylvania, he developed an interest in business. Med school felt like memorization and regurgitation of facts, he said, while business classes offered nuance and decision-making with no rote answers.
One moment sharpened the pivot. While assisting with a surgery, he overheard two well-respected surgeons say they wouldn't want their own children going into medicine. That stuck with him.
Beal earned his MD but skipped a residency. He joined McKinsey, the consulting giant, then left to spend more time with his kids. After an earlier startup, he co-founded Dyve Biosciences in 2014. The company's technology delivers therapeutic agents through the skin in a noninvasive way, targeting the acidic environment that cancer tumors thrive in.
What changed when the CEO became the patient?
For years, Beal ran Dyve as a scientist. "I was very much a scientist, focused on solving scientific problems," he said. "I knew our work would impact real people, but I very much came at the work through an empirical lens."
His mother's illness broke that distance. She survived breast cancer, but eight years later received a pancreatic cancer diagnosis that killed her within weeks. Then came his own.
He had sat in boardrooms discussing cancer infusions many times. He had never sat in an infusion center or an oncologist's waiting room. "Being in these spaces as a patient was incredibly emotional," he said. "It was eye-opening about not only the reality of cancer, but also the work I was doing."
His medical background helped in some ways — he knew the chemotherapy drugs he was taking. Insurance was another matter. He expected navigating coverage would be easy given his expertise; instead, he called it a nightmare even for someone who knows the system well.
Beal took a two-year sabbatical during treatment. It took that long to feel like himself again. His team was kind enough to say they didn't notice his brain fog, he said, but he did.
A company rebuilt around the patient
When he returned, his thinking about the business had changed. "Now, I'm entirely focused on the patient experience," Beal said. "I understand more acutely that long trials and timelines mean less hope for patients who have been told they have no more options to explore."
The shift is strategic, not just personal. Dyve's noninvasive transdermal delivery targets tumor acidity — an approach whose value depends on reaching patients who have run out of alternatives. A CEO who has been that patient now sets the priorities.
"I'm driven by emotion and my own experience now, more than science," he said.
He hasn't abandoned the commercial logic. "It takes capital to drive innovation, and I want to build a successful business where investors do well," Beal said. "But what drives me is patient outcomes."
The stakes are personal three times over. Beal's mother died of pancreatic cancer. His father died of cancer more recently. Beal himself went through two years of treatment.
"I want people like me, my mom, and my dad — who died of cancer more recently — to have access to better treatments," he said. "Even if that's all that happens with my business, I would be thrilled."
For a biotech founded in 2014, the question now is whether a founder's crash course in the patient's side of oncology can accelerate what a decade of lab-first leadership built.
Source: feeds.businessinsider.com
More from Amara Osei
Show full bio
Senior reporter covering companies, deals and strategy in entrepreneurship, startups and venture funding at Business Bearings.
2,157 articles